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Abstract 
Introduction: Immune checkpoint inhibitors exhibit robust antitumor activity in melanoma 
treatment but can induce highly toxic immunogenic effects. This case details an uncommonly 
severe adverse reaction to immune therapyand demonstrates the importance of identifying 
toxicities early to avoid adverse treatment outcomes. 
Presentation of Case: We present a patient who received anti-PD1 immunotherapy, nivolumab, 
as a second-line treatment for stage IV resected melanoma. The patient experienced several 
immune-related adverse effects and was diagnosed with myasthenia gravis. Despite receiving 
steroid, immunoglobin, and plasmapheresis treatment, the patient passed away.  
Conclusion: This case highlights the importance of closely monitoring and quickly addressing 
symptoms of nivolumab toxicity. Rapid institution of immunosuppressive therapy is not always 
successful. 
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Introduction 
While immune check-point inhibitors are highly efficacious in melanoma treatment, they may induce 
toxic and life-threatening effects[1]. Among immunotherapy treatments indicated for melanoma, the 
anti-programmed cell death 1 (PD-1) antibody nivolumab has one of the lowest rates of severe adverse 
events[2,3]. Additionally, nivolumab has shown similar efficacy and toxicity in both young and older, 
higher-risk patient populations[4]. Despite this efficacy and relative safety, rare and life-threatening 
adverse events have been reported[3,5–9].  
Here we discuss the case of a 75-year-old male experiencing severe immune-related adverse 
effects including myasthenia gravis (MG) following just two doses of nivolumab treatment.  Despite 
subsequent steroid, immunoglobin, and plasmapheresis treatments, the patient passed away within 
months of first experiencing adverse effects. This case adds to the growing number of reports of MG 
associated with nivolumab treatment and underscores the need for careful observation and aggressive 
treatment of side effects.  
Case Presentation 
A 75-year-old male presented with stage IB melanoma (T2aN0M0) localized to the left ear in 2014.  
The patient underwent a negative margin excision of the tumor with no evidence of disease (NED) 
remaining. Two years later, the patient received a computed tomography (CT) scan revealing a 3mm 
nodule in the lung. A CT plus positron emission tomography (PET) scan was performed five months 
later at which time the tumor had grown to 8mm and exhibited a standardized uptake value (SUV) of 
2.7. Due to suspected malignancy, the nodule was resected, and a pathology report revealed malignant 
melanoma felt to be stage IV with NED.  The patient was started on an immune check-point inhibition 
treatment trial pairing nivolumab together with randomized vaccine or no vaccine. The patient was 
randomized to the no vaccine group and received a 240mg IV dose of nivolumab every two weeks.  
Upon presenting for a third dose of nivolumab, the patient endorsed diplopia, diffuse muscle 
aching and pain, and shortness of breath. Testing was ordered and the third dose of nivolumab was 
withheld due to suspected toxicity. The patient was later called into the ER when lab results revealed 
severely elevated enzyme levels.  
Elevated CPK (6674 U/L), LDH (1535 U/L), and Aldolase (123.5 U/L) indicated myositis. 
Hepatitis and myocarditis were also suspected due to elevated AST/ALT (744/475 U/L) and troponin 
(2.69) respectively. Steroid treatment with prednisone was initiated. Following hypoxemic respiratory 
failure days later, the patient was transferred to the critical care unit. Further lab testing revealed 
normal GGT (20) levels ruling out hepatitis. An MRI of the brain revealed no metastasis and a nerve 
conduction velocity test indicated no motor neuropathy. These test results eliminated brain metastases 
and neuritis as potential diagnoses.  
Further lab work showed positive acetylcholine receptor antibody (38%), acetylcholine 
receptor blocking antibody (3.15 nmol/L), and mestinon tests. Based on these results and the clinical 
picture of diplopia, respiratory weakness, and bulbar weakness, MG was suspected.The patient 
subsequently received additional steroid and mestinon treatment. Lab results showing normal CPK, 
AST/ALT, and LDH levels indicated myositis and myocarditis had resolved, however MG symptoms 
remained. The patient began daily plasmapheresis(x5) and later immunoglobin(x2) treatment and 
showed improvement over the following two weeks. The patient was discharged into the care of a 
nursing home about a month after being admitted into the hospital and passed away shortly thereafter. 
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Discussion 
A literature review revealed six cases previously reported of MG associated with nivolumab treatment 
for various cancer types. Each of these cases showed a similar clinical picture of fatigue, muscle 
weakness, and diplopia among other symptoms.  In three of the reported cases, the patients recovered 
following MG treatment. Two of these cases required only mestinon or only prednisone treatment for 
symptoms to resolve[8,10]. The third case required prednisone, mestinon, immunoglobin and 
plasmapheresis to resolve MG-related symptoms. This case was particularly like the one presented 
here as the patient was also diagnosed with myositis related to nivolumab treatment. However, unlike 
the case presented, the patient’s symptoms arose following just one round of nivolumab treatment. 
Additionally, these symptoms were resolved following a similar treatment protocol that proved 
unsuccessful for the patient discussed in this case[11].  
Two additional cases of nivolumab-induced MG resulted in patient death following similar 
treatment protocol used in this case[5,9]. The sixth and final case reported was of a patient who 
developed MG under a dual nivolumab and ipilimumab treatment protocol[7]. Ipilimumab has 
previously been associated with MG, but the growing number of nivolumab-related cases reveal the 
high importance of closely monitoring patient reactions to the drug. Additionally, while previous 
research has shown no significant difference in immune checkpoint inhibitor toxicity between young 
and older patients, in all cases discussed here, the patients were over the age of 65[4]. This indicates 
more research is necessary to determine markers for at risk patients. Lastly, immunosuppressant 
therapyin combination with nivolumab treatment has been suggested to mitigate potential toxic side-
effects. Given the severity of symptoms in this case, immunosuppressant therapy may have been 
beneficial. Identifying markers for at risk patients would help determine who could benefit from 
immunosuppressant therapy when receiving nivolumab treatment.  
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